

Supplementary material

**Table S1: Overview of AOMs assessed in the literature**

Author, year	AOM								
	Short-term treatment of obesity (< 3 months)				Long-term treatment of obesity (> 3 months)				
	Diethylpropion	Phendimetrazine	Phentermine	Benzphetamine	Orlistat	Phentermine-topiramate	Bupropion-naltrexone	Liraglutide	Semaglutide
Almazan, 2023 <sup>1</sup>	x	x	x	x	x	x	x	x	x
Dieguez, 2021 <sup>2*†</sup>									
Lyu, 2022 <sup>3</sup>	x	x	x	x	x	x	x	x	
Hughes, 2022 <sup>4</sup>	x	x	x	x	x	x	x	x	
Watkins, 2022 <sup>5</sup>					x	x	x	x	
MacEwan, 2021 <sup>6</sup>	x	x	x	x	x	x	x	x	
Elangovan, 2021 <sup>7</sup>	x	x	x	x	x	x	x	x	
Hampp, 2013 <sup>8</sup>	x	x	x	x	x				
US GAO, 2019 <sup>9*</sup>	x	x	x	x	x	x	x	x	

Notes: \*Grey literature sources; †AOMs not specified.

Abbreviations: AOM, anti-obesity medication; GAO, Government Accountability Office; US, united states.

**References**

1. Almazan E, Schwartz JL, Gudzone KA. Use of medications associated with weight change among participants in the All of Us research programme. *Clinical obesity*. 2023;13(5):e12609.
2. Gabriela Dieguez F, Bruce Pyenson F, Tomicki S, Charles Steffens F. MILLIMAN REPORT. 2021.
3. Lyu B, Chang AR, Inker LA, Selvin E, Grams ME, Shin J-I. Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: a population-based study. *The Lancet Regional Health–Americas*. 2022;11.
4. Hughes S, Dietz WH, Gallagher C. Coverage for obesity prevention and treatment: analysis of state employee health plans and use of benefits. *Obesity*. 2022;30(8):1573-1578.
5. Watkins S, Toliver JC, Kim N, Whitmire S, Garvey WT. Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study. *Journal of Managed Care & Specialty Pharmacy*. 2022;28(10):1066-1079.

6. MacEwan J, Kan H, Chiu K, Poon JL, Shinde S, Ahmad NN. Antiobesity medication use among overweight and obese adults in the United States: 2015–2018. *Endocrine Practice*. 2021;27(11):1139-1148.
7. Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity—trends using a population level national database. *Obesity Surgery*. 2021;31:1105-1112.
8. Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2013;33(12):1299-1307.
9. United States Government Accountability Office. Obesity drugs: Few adults used prescription drugs for weight loss and insurance coverage varied. 2019.